Home › Funds › Paradigm Biocapital Advisors LP › JBIO
Paradigm Biocapital Advisors LP position in JBIO
JADE BIOSCIENCES INC · Health Care
Paradigm Biocapital Advisors LP reported holding 6,053,268 shares of JBIO (JADE BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$85.0M, representing 1.69% of its reported portfolio and ranking #15 among its reported holdings. Paradigm Biocapital Advisors LP has disclosed JBIO holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Paradigm Biocapital Advisors LP's JBIO position evolved
Paradigm Biocapital Advisors LP first disclosed a stake in JBIO in Q2 2026 at 2,857,405 shares (US$63.5M). The position peaked in Q3 2026 at 6,053,268 shares, worth US$85.0M. Across 2 filings, Paradigm Biocapital Advisors LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 6,053,268 shares valued at US$85.0M — an increase of 3,195,863 shares quarter over quarter.. Notable position changes include a 112% increase in Q3 2026 (shares rose 15% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 2.86M | $63.49M | New |
| Q3 2026 | 6.05M | $85.05M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About JBIO and 13F data
JBIO (JADE BIOSCIENCES INC) is a Health Care company. 86 other funds we track also report a position in JBIO — the largest reported positions include Fairmount Funds Management LLC (US$101.2M), RA CAPITAL MANAGEMENT, L.P. (US$81.6M), Venrock Adviser, LLC (US$71.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding JBIO
- Fairmount Funds Management LLC 4.55M sh · $101.18M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 3.67M sh · $81.57M · Q2 2026
- Venrock Adviser, LLC 3.22M sh · $71.56M · Q2 2026
- Bellevue Group AG 3.06M sh · $67.95M · Q2 2026
- Avidity Partners Management LP 1.70M sh · $37.79M · Q2 2026
- Soleus Capital Management, L.P. 1.55M sh · $34.46M · Q2 2026
- BAKER BROS. ADVISORS LP 1.23M sh · $27.34M · Q2 2026
- Remedium Capital Partners, LLC 1.81M sh · $25.40M · Q3 2026
- Foresite Capital Management VI LLC 886.67K sh · $19.70M · Q2 2026
- Samsara BioCapital, LLC 736.24K sh · $16.36M · Q2 2026
- Versant Venture Management, LLC 991.78K sh · $13.93M · Q3 2026
- ACORN CAPITAL ADVISORS, LLC 986.76K sh · $13.86M · Q3 2026
More on Paradigm Biocapital Advisors LP
FAQ
How long has Paradigm Biocapital Advisors LP held JBIO?
Paradigm Biocapital Advisors LP has disclosed JBIO holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Paradigm Biocapital Advisors LP's current position in JBIO?
As of Q3 2026, Paradigm Biocapital Advisors LP holds 6.05M shares of JBIO (JADE BIOSCIENCES INC), valued at $85.05M, representing 1.69% of its reported portfolio and ranking #15.
Has Paradigm Biocapital Advisors LP been buying or selling JBIO?
In the latest 13F filing (Q3 2026), Paradigm Biocapital Advisors LP increased its position in JBIO. The position peaked in Q3 2026 at 6.05M shares.
Which other funds hold JBIO?
Other major institutional holders of JBIO include Fairmount Funds Management LLC, RA CAPITAL MANAGEMENT, L.P., Venrock Adviser, LLC, among 86 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.